Liu Jia, Ng Diana, Lee James, Stalley Paul, Hong Angela
Central Clinical School, Faculty of Medicine, University of Sydney, Camperdown, NSW, Australia.
Department of Radiation Oncology, Mater Hospital, Genesis Cancer Care, St Leonards, NSW, Australia.
Radiat Oncol. 2016 Mar 2;11:34. doi: 10.1186/s13014-016-0611-0.
Definitive radiotherapy is often used for chest wall desmoid tumours due to size or anatomical location. The delivery of radiotherapy is challenging due to the large size and constraints of normal surrounding structures. We compared the dosimetry of 3D conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc radiotherapy (VMAT) to evaluate the best treatment option.
Ten consecutive patients with inoperable chest wall desmoid tumours (PTV range 416-4549 cm(3)) were selected. For each patient, 3DCRT, IMRT and VMAT plans were generated and the Conformity Index (CI), organ at risk (OAR) doses and monitor unit (MU) were evaluated. The Wilcoxon signed-rank test was used to compare dose delivered to both target and OARs.
The mean number of fields for 3DCRT and IMRT were 6.3 ± 2.1, 7.2 ± 1.8. The mean number of arcs for VMAT was 3.7 ± 1.1. The mean conformity index of VMAT (0.98 ± 0.14) was similar to that of IMRT (1.03 ± 0.13), both of which were significantly better than 3DCRT (1.35 ± 0.20; p = 0.005). The mean dose to lung was significantly higher for 3DCRT (11.9Gy ± 7.9) compared to IMRT (9.4Gy ± 5.4, p = 0.014) and VMAT (8.9Gy ± 4.5, p = 0.017). For the 3 females, the low dose regions in the ipsilateral breast for VMAT were generally less with VMAT. IMRT plans required 1427 ± 532 MU per fraction which was almost 4-fold higher than 3DCRT (313 ± 112, P = 0.005). Compared to IMRT, VMAT plans required 60 % less MU (570 ± 285, P = 0.005).
For inoperable chest wall desmoid tumours, VMAT delivered equivalent target coverage when compared to IMRT but required 60 % less MU. Both VMAT and IMRT were superior to 3DCRT in terms of better PTV coverage and sparing of lung tissue.
由于胸壁硬纤维瘤的大小或解剖位置,根治性放疗常被用于治疗此类肿瘤。由于肿瘤体积大以及周围正常结构的限制,放疗的实施具有挑战性。我们比较了三维适形放疗(3DCRT)、调强放疗(IMRT)和容积调强弧形放疗(VMAT)的剂量学,以评估最佳治疗方案。
选取10例连续的无法手术切除的胸壁硬纤维瘤患者(计划靶体积范围为416 - 4549 cm³)。为每位患者生成3DCRT、IMRT和VMAT计划,并评估适形指数(CI)、危及器官(OAR)剂量和监测单位(MU)。采用Wilcoxon符号秩检验比较靶区和危及器官所接受的剂量。
3DCRT和IMRT的平均射野数分别为6.3±2.1、7.2±1.8。VMAT的平均弧数为3.7±1.1。VMAT的平均适形指数(0.98±0.14)与IMRT(1.03±0.13)相似,两者均显著优于3DCRT(1.35±0.20;p = 0.005)。3DCRT对肺的平均剂量(11.9Gy±7.9)显著高于IMRT(9.4Gy±5.4,p = 0.014)和VMAT(8.9Gy±4.5,p = 0.017)。对于3例女性患者,VMAT在同侧乳房的低剂量区域通常较少。IMRT计划每次分割需要1427±532 MU,几乎是3DCRT(313±112,P = 0.005)的4倍。与IMRT相比,VMAT计划所需MU减少60%(570±285,P = 0.005)。
对于无法手术切除的胸壁硬纤维瘤,与IMRT相比,VMAT能提供相当的靶区覆盖,但所需MU减少60%。在更好的计划靶体积覆盖和肺组织保护方面,VMAT和IMRT均优于3DCRT。